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well-defined and diverse PBA patient population, showing statistically significant 
improvements in a range of validated clinical and HRQoL outcomes relevant for 
the treatment of PBA. CONCLUSIONS: The evidence base for off-label agents used 
for treatment of PBA is limited, relying on small often uncontrolled studies show-
ing ill-defined treatment effects and little or no safety tracking. DM/Q is the only 
treatment for PBA that has demonstrated efficacy in well-conducted clinical trials 
in patients with varied neurological disorders.
PND11
TerifluNomiDe ShowS CoNSiSTeNT CliNiCal effiCaCy oN Severe 
relaPSeS aCroSS TemSo aND Tower: 2 PhaSe 3 TrialS
Leist T.P.1, Stangel M.2, Macdonell R.3, Mäurer M.4, Thangavelu K.5, Truffinet P.6, Bozzi S.7, 
Dive-Pouletty C.6, Freedman M.S.8
1Thomas Jefferson University Hospital, Philadelphia, PA, USA, 2Medizinische Hochschule 
Hannover, Hannover, Germany, 3Austin Health, Heidelberg, Australia, 4Caritas Krankenhaus Bad 
Mergentheim, Bad Mergentheim, Germany, 5Genzyme, a Sanofi company, Cambridge, MA, USA, 
6Genzyme, a Sanofi company, Chilly-Mazarin, France, 7Sanofi, Chilly-Mazarin, France, 8University 
of Ottawa and the Ottawa Hospital Research Institute, Ottawa, ON, Canada
OBJECTIVES: Teriflunomide is a once-daily oral immunomodulator approved for 
relapsing-remitting MS. Here we report the key efficacy, safety, and post hoc analy-
ses from the randomized, placebo-controlled phase 3 trials TEMSO (NCT00134563) 
and TOWER (NCT00751881). METHODS: In TEMSO/TOWER, a total of 1088/1169 
patients with relapsing MS were randomized (1:1:1) to once-daily teriflunomide 14 
mg, teriflunomide 7 mg, or placebo. Treatment duration was 108 weeks (TEMSO) or 
variable, based on time of enrollment (TOWER; 48–152 weeks, ending 48 weeks after 
last patient randomized). Primary and key secondary endpoints were annualized 
relapse rate (ARR) and disability progression confirmed for 12 weeks. Additional 
endpoints included safety and tolerability. Post hoc analyses examined the effect 
of teriflunomide on 5 severe relapse outcomes: (A) relapses with sequelae defined 
by increase in Expanded Disability Status Scale score/Functional Score 30 days 
postrelapse; (B) relapses with investigator-defined sequelae; (C) severe relapses by 
Panitch definition; (D) relapses leading to hospitalization; and (E) relapses requir-
ing treatment with intravenous corticosteroids. RESULTS: In TEMSO/TOWER, 
teriflunomide 14 mg significantly reduced both ARR and disability progression vs 
placebo. Teriflunomide 7 mg significantly reduced ARR but not disability progres-
sion. Teriflunomide 14 mg significantly reduced annualized rates of severe relapse 
outcomes compared with placebo in TEMSO/TOWER by: (A) 36.2% (P= 0.0011)/36.6% 
(P= 0.0021); (B) 52.6% (P< 0.0001)/53.5% (P= 0.0004); (C) 38.5% (P= 0.0286)/52.5% 
(P= 0.0015); (D) 59.3% (P< 0.0001)/33.6% (P= 0.0155); and (E) 33.7% (P= 0.0003)/35.7% 
(P= 0.0002). Teriflunomide 7 mg also reduced annualized rates of severe relapses, 
although not significantly in all definitions. Both teriflunomide doses showed simi-
lar safety profiles across the 2 studies. CONCLUSIONS: Teriflunomide 14 mg has 
shown consistent and significant positive effects on ARR and disability progression 
in 2 phase 3 studies. Teriflunomide also reduces severe relapses as measured by 
various relapse definitions, which may reduce relapse-related healthcare costs and 
improve patients’ quality of life.
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OBJECTIVES: Multiple sclerosis (MS) disease progression is measured by the 
Expanded Disability Status Scale (EDSS). UK MS clinical guidelines1recommend that 
patients discontinue treatment with disease modifying therapies (DMTs) on reach-
ing EDSS ≥ 7.0, or experiencing non-relapsing secondary progressive MS (SPMS). This 
study derived the time for patients to reach EDSS ≥ 7.0 or SPMS from EDSS 4.0 or 
5.0, for patients treated with delayed-release dimethyl fumarate 240mg (DMF; also 
known as gastro-resistant DMF), or no DMT treatment. METHODS: The time taken 
to reach relapsing-remitting MS (RRMS) EDSS ≥ 7.0, or SPMS (any EDSS state) from 
EDSS 4.0 or 5.0 was estimated from transition probability matrices using algebraic 
techniques from Mandel 20072: the time to EDSS ≥ 7.0 or SPMS was derived for each 
matrix (DMF, untreated) by using matrix multiplication to estimate the proportion of 
patients who had reached these states over time. The transition matrix for untreated 
patients was derived using placebo arm data from clinical trials3,4(for RRMS popula-
tion) and London Ontario dataset (for transitions from RRMS to SPMS). The transition 
matrix for DMF was estimated by applying treatment effect on disability progression 
(sourced from a mixed treatment comparison), to the probability of progressing in 
the untreated matrix. Probabilistic sensitivity analysis was conducted to estimate 
95% confidence intervals (CIs). RESULTS: The time for progression from EDSS 4.0 
to ≥ 7.0 or SPMS was 8.53 years (95% CI: 7.05-10.25) for patients treated with DMF 
and 5.90 years (95% CI: 5.59-6.24) for untreated patients. The time from EDSS 5.0 to 
≥ 7.0 or SPMS was 5.28 years (95% CI: 4.32-6.37) for patients treated with DMF and 
3.64 years (95% CI: 3.34-3.96) for untreated patients. CONCLUSIONS: Our analysis 
showed that DMF therapy was associated with a longer time interval between EDSS 
4.0 or 5.0 and progression to EDSS ≥ 7.0 or SPMS relative to no DMT treatment.
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OBJECTIVES: Teriflunomide and dimethyl fumarate (DMF), oral therapies for 
relapsing-remitting MS, have demonstrated efficacy in clinical trials on magnetic 
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OBJECTIVES: IPX066, an extended-release capsule formulation of carbidopa-levo-
dopa (CD-LD), is designed to produce a rapid increase in plasma levodopa concen-
trations similar to immediate-release CD-LD (IR), but with sustained plasma levels 
allowing dosing every 6 hours. This post hoc analysis investigated whether baseline 
Parkinson’s disease (PD) severity influenced the patient reported efficacy of IPX066 
vs. IR in advanced PD patients. METHODS: IPX066 was evaluated in a randomized, 
double-blind, Phase 3 study vs. IR CD-LD for 13 weeks (N= 393). Patients were split 
into subgroups of higher and lower disease severity based on median baseline “off” 
time (5.67 hr) and Unified Parkinson’s Disease Rating Scale (UPDRS) Parts II+III 
(score: 32). Patient Global Impression (PGI), and the change from baseline in “off” 
time and “on” time with troublesome dyskinesia by PD diary were analyzed for 
each subgroup. RESULTS: IPX066 significantly improved PGI (P< .0001) and “off” time 
(P< .0001) compared with IR CD-LD in the overall randomized population. IPX066 
significantly improved PGI scores compared with IR CD-LD in both higher severity 
subgroups (P< .001) and lower severity subgroups (P< .02). Numerical improvements 
from baseline in “off” time were seen with IPX066 vs. IR CD-LD in each disease sever-
ity subgroup. The improvements in “off” time were significantly greater for IPX066 
vs. IR CD-LD in the higher severity “off” (P< .0001) and in both the higher (P= .02) and 
lower severity (P= .0001) UPDRS subgroups. The improvement by IPX066 compared 
to IR CD-LD in the lower severity “off” subgroup did not reach significance (P= .11), 
possibly due to a floor effect. IPX066 did not significantly worsen “on” time with trou-
blesome dyskinesia compared to IR CD-LD in any subgroup (P> .14). CONCLUSIONS: 
Advanced PD patients reported higher global impression of change and greater 
improvements in “off” time without worsening troublesome dyskinesia after treat-
ment with IPX066 compared with IR CD-LD, regardless of disease severity subgroup.
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OBJECTIVES: We performed a systematic review of randomized controlled tri-
als (RCTs) to estimate the efficacy of melatonin versus placebo or other hypnotic 
agents on the improvement of sleep quality and quantity in patients with primary 
insomnia. METHODS: We searched the published literatures in eight electronic 
databases, including Ovid-Medline, EMBASE, the Cochrane Library, and five Korean 
databases through October 2014. We included articles comparing efficacy for sleep 
between melatonin and placebo or other hypnotics among primary insomnia 
patients. The quality of studies was evaluated by using the Cochrane’s risk of bias. 
The mean difference (MD) or standardized mean difference (SMD) was calculated 
using the random-effects method for each study outcome. To assess heterogene-
ity of inter-trial, we used the I2-statistic. Subgroup-analyses were performed by 
assessment tools, study designs, ages and dosage of melatonin. Funnel plots were 
used to assess publication bias. RESULTS: Eighteen RCTs were identified and the 
comparison groups of all included trials were placebo. Compared with placebo, 
melatonin significantly reduced sleep onset latency (MD: -6.58 min [95% confidential 
interval (CI): -9.75 to -3.41], p < 0.0001), and increased total sleep time (MD: 20.56 
min [95% CI: 4.70 to 36.41], p = 0.01) and sleep efficiency (MD: 3.47% [95% CI: 0.37 to 
6.58], p = 0.03). Sleep quality was also improved (SMD: 0.22 [95% CI: 0.03 to 0.40], p = 
0.02) in melatonin group but this result was concluded based on a small number of 
studies. In subgroup-analyses for each outcome, there was no clinically remarkable 
finding. We did not find any evidence of statistical heterogeneity and publication 
bias. CONCLUSIONS: Melatonin showed to be effective for sleep in comparison 
with placebo, thus can be an effective option for the treatment of insomnia. Further 
studies are needed to conclude safety profiles, economic usefulness and tolerance 
of melatonin.
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OBJECTIVES: PBA is a neurologic disorder characterized by involuntary, uncontrol-
lable laughing and/or crying episodes that are often incongruent with the patient’s 
internal emotional state; PBA has also been called pathological laughing/crying, 
emotionalism, etc. Until FDA approval of dextromethorphan/quinidine (DM/Q) in 
2010, multiple agents including antidepressants, antipsychotics, dopamine ago-
nists and sedatives were used off-label for the management of PBA symptoms. 
We conducted a systematic review of therapies (licensed and unlicensed) for PBA 
symptoms to evaluate their relative clinical effectiveness METHODS: Databases: 
Medline, Medline in process, Embase and the Cochrane central register of con-
trolled trials; conference abstracts were searched in Embase. Study type: RCTs and 
non-RCTs in adult patients with PBA/PBA-like symptoms (pathological laughing/
crying, emotionalism, etc). Interventions: DM/Q, antidepressants, antipsychotics, 
dextromethorphan and quinidine alone. Outcome measures: change from baseline 
in various measures of PBA/emotionalism symptoms or symptom burden (NPI, 
SF-36, PRS scores and the caregiver strain index (CSI)). RESULTS: Nine RCTs and 
three observational studies were included. Among off-label drugs, six RCTs of 3 
SSRIs and 2 TCAs showed improvements in disparate PBA symptom measures, only 
1 used a validated symptom measure. These studies were small (N= 6-28) using 
mostly stroke patients. They were heterogeneous on how they defined/diagnosed 
PBA and varied in duration (1.4-24 weeks). As such, no formal evidence synthesis 
was possible. Three RCTs and one open label trial investigating DM/Q included a 
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OBJECTIVES: In the phase 3 CARE-MS II study (NCT00548405), alemtuzumab dem-
onstrated a reduction in annualized relapse rate (49%) and sustained accumulation 
of disability (42%) versus subcutaneous interferon beta-1a 44 μ g (both P< 0.01). This 
analysis assessed the budget impact (BI) of adding alemtuzumab to a formulary 
containing approved disease-modifying therapies (DMTs) for multiple sclerosis (MS) 
in a hypothetical 100,000-member US health plan. METHODS: Alemtuzumab was 
administered as 2 annual treatment courses to patients with relapsing-remitting 
MS inadequately responding to prior therapy, with as-needed retreatment in an 
extension (NCT00930553). A 5-year BI analysis from a US payer perspective was 
developed with US-approved DMTs included as comparators. The model accounted 
for the effect of DMTs on relapses, but not disability. Key cost inputs included drug 
acquisition, drug administration and monitoring, adverse events (AEs), and cost 
of relapse. Percentage of patients taking alemtuzumab was projected to increase 
gradually from 1.6% in its first year of use to 7.5% by Year 5. RESULTS: Relapse costs 
were reduced beginning the first year of alemtuzumab formulary inclusion, resulting 
in annual relapse cost savings of $25,045 by Year 5. Total costs attributable to DMT 
acquisition, AEs, and monitoring increased with the introduction of alemtuzumab 
($188,516 by Year 5). Total budget impact peaked in Year 4 (plan member per month 
[PMPM] cost= $0.17) and decreased by Year 5 (PMPM= $0.14). This downward trend is 
attributable to decreased drug acquisition and administration costs due to the dura-
bility of alemtuzumab’s effect and increased relapse cost savings. CONCLUSIONS: 
Reduction in relapses, the unique dosing schedule, and durable efficacy for most 
patients in the absence of retreatment, provide significant cost offsets to alemtu-
zumab formulary inclusion compared to formularies not including alemtuzumab. 
The model provides conservative estimates by excluding disability costs, which are 
a major contributor to the cost of caring for MS patients.
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OBJECTIVES: To estimate the budget impact of adding peginterferon beta-1a, a new 
interferon requiring injections only every two weeks for the treatment of relapsing 
forms of multiple sclerosis (MS), to a managed care formulary in the US. METHODS: 
An Excel model was developed to compare the drug-related costs of the current mix 
of treatments with the costs of an estimated treatment mix including peginter-
feron beta-1a for a managed care organization (MCO) with 1,000,000 covered lives. 
The number of people with relapsing forms of MS was estimated using published 
prevalence data. Treatment share of peginterferon beta-1a was assumed to increase 
from 3% in 2014 to 7% in 2018 taken proportionately by treatment shares from the 
other interferons indicated for MS. Drug costs included: acquisition costs adjusted 
by patient payments and dispensing fees as well as administration, monitoring, 
and adverse event costs. Annual relapse treatment costs were estimated using the 
relative risk reduction of a relapse for each DMT derived using a mixed-treatment 
comparison analysis A one-way sensitivity analysis was performed. RESULTS: The 
resonance imaging and clinical outcomes. Despite challenges in comparing out-
comes across studies, exploratory analyses of treatment effects can be compared 
informally using relative reductions in a specific endpoint. The number needed to 
treat (NNT) to prevent an event is an important outcome to consider for any com-
parisons within the field of MS. METHODS: NNTs were derived using data from 
studies with teriflunomide 14 mg (TEMSO, NCT00134563; TOWER, NCT00751881) or 
DMF (DEFINE, NCT00420212; CONFIRM, NCT00451451) based on the inverse of abso-
lute differences between treatment and placebo groups. RESULTS: Teriflunomide 
studies included patients with progressive disease; patients in DEFINE had slightly 
lower baseline Expanded Disability Status Scale scores. Teriflunomide and DMF 
significantly reduced risk of relapse (all studies). NNTs to prevent 1 relapse were 
similar across all studies (5.9 [TEMSO], 5.6 [TOWER], 5.3 [DEFINE], 5.6 [CONFIRM]). 
Risk of disability progression sustained for 12 weeks was significantly reduced in 
TEMSO, TOWER, and DEFINE but not CONFIRM. Corresponding NNTs to prevent 
disability progression were 13.8, 17.4, 10.8, and 30.2. Risk of relapse leading to hos-
pitalization was significantly reduced in TEMSO and TOWER but not in DEFINE and 
CONFIRM. Corresponding NNTs were lower in TEMSO (12.5) and TOWER (20) than 
in DEFINE (50) and CONFIRM (50). Safety data and corticosteroid use will be pre-
sented. CONCLUSIONS: Using the NNT approach, we demonstrate a comparable 
effect size for teriflunomide and DMF on relapses. NNTs to prevent disability pro-
gression with teriflunomide showed a consistent significant reduction in risk vs 
placebo in both TEMSO and TOWER. For DMF, comparable NNTs were observed only 
in DEFINE, and not in CONFIRM. Reduction of risk for relapse leading to hospitaliza-
tion was significant only for teriflunomide.
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OBJECTIVES: In Brazil, there are three first line interferonβ for relapsing remit-
ting multiple sclerosis (RRMS): Interferonβ 1a (Rebif® and Avonex®) and 1b 
(Betaferon®). Our aim is to produce a systematic review with meta-analysis 
to compare those Interferon’s-β efficacies in RRMS. METHODS: We searched 
MEDLINE, CENTRAL and others database to identify randomized controlled trials 
evaluating Interferons-β in RRMS. Clinical outcomes evaluated were reduction of 
relapse risk at 12, 24 months, and reduction of disability progression measured 
by the Expanded Disability Status Scale. Aggregated data was evaluated using 
a series of pairwise fixed-effects meta-analyses. RESULTS: From 465 articles 
found, 9 fit the inclusion criteria (5 placebo-controlled and 4 head-to-head tri-
als). The analysis showed that Rebif® reduces relapses at 12 months (RR= 0,85; 
95%CI= 0.77-0.93; P= 0.0005), 24 months (RR= 0.85; 95%CI= 0.77-0.92; P= 0.0002) and 
disability progression at 24 months (RR= 0.76; 95%CI= 0.61-0.95; P= 0.02) compared 
to placebo. Betaferon® reduces relapses at 24 months (RR= 0.89; 95%CI= 0.81-0.99; 
P= 0.03) but does not differ significantly from placebo in relapses over 12 months 
or disability progression. Avonex® does not differ significantly from placebo at 
any endpoint. From the 4 head-to-head trials: two compared Betaferon® and 
Avonex® showing Betaferon® superior in reducing disability progression at 24 
months (RR= 0.76; 95%CI= 0.59-0.9; P= 0.03); one comparing Rebif® to Avonex® 
showed superiority of Rebif® in decreasing relapses at 24 months and time to 
first relapse; one showed no differences in annual relapses between Betaferon® 
and Rebif®. CONCLUSIONS: Betaferon® did not reduce relapse risk in 12 months 
and disability progression. Avonex® did not demonstrate significant reduction 
in relapse risk reduction at 12 and 24 months as well as reduction of disability 
progression when compared to placebo. Among the approved first-line treatment 
interferon-β only Rebif® demonstrate statistically significant lower risk of relapse 
in 12 and 24 months as well as reduction in disability progression.
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OBJECTIVES: Parkinson’s disease (PD) is a neurodegenerative disorder causing pro-
gressive motor impairment and disability. The effects of PD are measure throughout 
the Unified Parkinson’s Disease Rating Scale (UPDRS). PD treatments include drugs 
that increase the functional ability of the underactive dopaminergic system or that 
reduce the excessive influence of excitatory cholinergic neurons. The purpose of this 
study was to conduct an indirect comparison of the efficacy of different alternatives 
of early treatment for Parkinson’s disease regarding the UPDRS. METHODS: We 
realized a systematic literature review in eigth data base with keys word: Parkinson 
disease, early treatment, levodopa, pramipexole, rasagiline, selegiline and placebo. 
The inclusion criteria were patients with parkinson’s disease in Hoehn and Yahr I, 
2 or 3, UPDRS scale, lenguaje spanish and english, since January 1994 to May 2014. 
Results of all trials were analyzed simultaneously with a Bayesian Mixed Treatment 
Comparison (MTC) to obtain the relative efficacy into the treatments. RESULTS: 
There were 1080 clinical trials (CT), only five meeting the inclusion criteria: levodopa 
(1CT), pramipexole (1 CT), rasagiline (2CT) and selegiline (1CT), using a random 
model levodopa showed the best punctuation in UPDRS (probability= 0.61) when all 
the treatments were compared. Also, it showed a mean difference of 7 relative to 
placebo, CrI (0.14-14); 2.2 relative to pramipexole CrI (-7.5- 12); 3.5 relative to rasagil-
ine, CrI (-4.8-12) and 1.6 relative to selegiline, CrI (-8.3-12). CONCLUSIONS: Findings 
of this study indicate that Levodopa provides a greater disability and impairment 
reduction in patients with Parkinson disease (measured by UPDRS) patients than 
pramipexole, rasagiline and selegiline as first treatment option to early parkinson’s 
disease in monotherapy.
